■肥胖流行增加了非酒精性脂肪性肝病(NAFLD)在普通和慢性乙型肝炎(CHB)人群的风险。我们的研究旨在确定基于控制衰减参数(CAP)和流行病学的CHB患者NAFLD的患病率,临床,和与严重肝脂肪变性相关的病毒学因素。
■加拿大乙型肝炎网络队列用于提供人口统计的横截面描述,合并症,抗病毒治疗,和乙型肝炎病毒(HBV)测试。通过瞬时弹性成像和CAP测量肝纤维化和脂肪变性,分别。任何等级和严重脂肪变性定义为CAP>248和>280dB/m,分别。晚期肝纤维化定义为瞬时弹性成像测量>10.7kPa。
■在1178例CHB患者中(中位年龄:47.4%,男性占57.7%,75.7%亚洲人,非洲13%,6.5%白色,86%HBVe抗原阴性,HBVDNA中位数为2.44log10IU/mL,42.7%接受治疗),任何级别和严重脂肪变性的患病率分别为53%和36%,分别。在多变量分析中,肥胖是严重脂肪变性的重要预测因子(校正比值比:5.046,95%置信区间:1.22-20.93).严重脂肪变性是与病毒载量相关的决定因素(调整比值比:0.385,95%置信区间:0.20-0.75,P<.01;r=-0.096,P=.007),无论抗病毒治疗,年龄,丙氨酸转氨酶水平.
■在这个庞大的多民族CHB人口中,肝脂肪变性是常见的。严重的脂肪变性与更高的纤维化独立相关,但HBVDNA呈阴性,无论抗病毒治疗史。
UNASSIGNED: The obesity epidemic has increased the risk of nonalcoholic fatty liver disease (NAFLD) in both the general and chronic hepatitis B (CHB) populations. Our study aims to determine the prevalence of NAFLD in patients with CHB based on controlled attenuation parameter (CAP) and the epidemiological, clinical, and virological factors associated with severe hepatic steatosis.
UNASSIGNED: The Canadian Hepatitis B Network cohort was utilized to provide a cross-sectional description of demographics, comorbidities, antiviral treatment, and hepatits B virus (HBV) tests. Liver fibrosis and steatosis were measured by transient elastography and CAP, respectively. Any grade and severe steatosis were defined as CAP >248 and >280 dB/m, respectively. Advanced liver fibrosis was defined as transient elastography measurement >10.7 kPa.
UNASSIGNED: In 1178 patients with CHB (median age: 47.4%, 57.7% males, 75.7% Asian, 13% African, 6.5% White, 86% HBV e antigen negative, median HBV DNA of 2.44 log10IU/mL, 42.7% receiving treatment), the prevalence of any grade and severe steatosis was 53% and 36%, respectively. In the multivariate analysis, obesity was a significant predictor for severe steatosis (adjusted odds ratio: 5.046, 95% confidence interval: 1.22-20.93). Severe steatosis was a determinant associated with viral load (adjusted odds ratio: 0.385, 95% confidence interval: 0.20-0.75, P < .01; r = -0.096, P = .007) regardless of antiviral therapy, age, and alanine aminotransferase levels.
UNASSIGNED: In this large multiethnic CHB population, hepatic steatosis is common. Severe steatosis is independently associated with higher fibrosis, but negatively with HBV DNA, regardless of antiviral therapy history.